Skip to main content

Table 2 Adverse events leading to discontinuation in > 2 patients in any single exposure period through 260 weeks of apremilast treatment by treatment period

From: Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis

Patients, n (%)

Apremilast-exposure period*

Weeks 0 to ≤ 52

Weeks > 52 to ≤ 104

Weeks > 104 to ≤ 156

Weeks > 156 to ≤ 208

Weeks > 208 to ≤ 260

30 mg twice daily (n = 721)

20 mg twice daily (n = 720)

30 mg twice daily (n = 520)

20 mg twice daily (n = 508)

30 mg twice daily (n = 443)

20 mg twice daily (n = 422)

30 mg twice daily (n = 401)

20 mg twice daily (n = 366)

30 mg twice daily (n = 364)

20 mg twice daily (n = 320)

Nausea

16 (2.2)

8 (1.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Diarrhea

15 (2.1)

6 (0.8)

1 (0.2)

0 (0.0)

0 (0.0)

1 (0.2)

0 (0.0)

0 (0.0)

1 (0.3)

0 (0.0)

Headache

11 (1.5)

4 (0.6)

0 (0.0)

0 (0.0)

1 (0.2)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Vomiting

6 (0.8)

1 (0.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Dizziness

4 (0.6)

2 (0.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Upper abdominal pain

3 (0.4)

4 (0.6)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.3)

0 (0.0)

0 (0.0)

Migraine

3 (0.4)

1 (0.1)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

Fatigue

3 (0.4)

2 (0.3)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.3)

0 (0.0)

0 (0.0)

  1. *Includes all patients who received apremilast during the time interval relative to the start of apremilast treatment